CD19 and lymphoma: Ongoing clinical investigations include Phase I trials focusing on PD-1 targeting in EBV-related cancers 188, along with Phase II studies evaluating therapies for CD19-positive leukemia and lymphoma (NCT03166878), as well as treatment-resistant or relapsed cases of these diseases189.